Multiple sclerosis (MS) is a disease that affects the brain and spinal cord. It happens when the body’s immune system ...

Getting at least 30 minutes of daily summer sun in the first year of life may mean a lower relapse risk for children who are diagnosed with multiple sclerosis (MS) later, according to a study ...

Getting at least 30 minutes of daily summer sun in the first year of life may mean a lower relapse risk for children who are diagnosed with multiple sclerosis (MS) later, according to a study ...

We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...

Getting at least 30 minutes of daily summer sun in the first year of life may mean a lower relapse risk for children who are ...

Experts in Australia and New Zealand have published the first consensus guidelines for the care of adults with MS in those ...

Biogen (BIIB) guided for a decline in earnings and revenue for 2025 amid ongoing challenges in its multiple sclerosis product category, despite reporting stronger-than-expected fourth-quarter results.

The company is expecting 2025 EPS to range from $15.25 to $16.25, below the $16.33 FactSet consensus. Revenue is expected to decline by a mid-single-digit percent on a constant currency basis, as ...

While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...

Detect, improves systemic sclerosis diagnosis with over 90% accuracy in capillaroscopy. The AI tool enhances capillary ...

Neighborhood disadvantage, or living in a poorer region, was linked to significantly shorter survival time for ALS patients ...

Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...